How should we follow the Crohn's disease patients in remission?

Kaynakça (1)

1. A Bitton, PL Dobkin, M D Edwardes et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008;57;1386-1392 2. Sahmoud T, Hoctin-Boes G, Modigliani R et al. Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1995;37:811-8. 3. Cosnes J, Carbonnel F, Beaugerie L et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31. 4. Seksik P, Nion-Larmurier I, Sokol H et al. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009;15:734-41. 5. Solem CA, Loftus EV Jr, Tremaine WJ et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12. 6. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9 7. Simonis B, Heine M, Heene DL, et al. Evaluation and validation of a Crohn's disease inflammatory activity index reflecting pattern of endoscopic severity. Scand J Gastroenterol 1998;33:283-8 8. Koelewijn CL, Schwartz MP, Samsom M et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-9. 9. Boirivant M, Leoni M, Tariciotti D et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10:401-5. 10. Consigny Y, Modigliani R, Colombel JF et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006;12:551-7. 11. D'Incà R, Dal Pont E, Di Leo V et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14. 12. Costa F, Mumolo MG, Ceccarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8. 13. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale- Update based on new evidence. Gastroenterology 2003; 124:544-60.